# Italy Host Cell Protein Testing Market > Italy Host Cell Protein Testing Market Research Report By Type (PCR-Based Assays, ELISA-based Assays, Mass Spectrometry-Based Assays, Others) and By End User (Contract Research Organizations, Biopharmaceutical Companies, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.82% - **2024:** $ 24.15 Million - **2025:** $ 25.56 Million - **2035:** $ 45 Million - **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Sartorius AG (DE), Lonza Group (CH), GenScript Biotech Corporation (CN), Charles River Laboratories (US), WuXi AppTec (CN), Bio-Rad Laboratories (US) **Report ID:** MRFR/LS/43209-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/italy-host-cell-protein-testing-market-44889 --- ## Market Summary ## **Italy Host Cell Protein Testing Market Overview:** As per MRFR analysis, the Italy Host Cell Protein Testing Market Size was estimated at 32.75 (USD Million) in 2023. The Italy Host Cell Protein Testing Market Industry is expected to grow from 34.5(USD Million) in 2024 to 78.5 (USD Million) by 2035. The Italy Host Cell Protein Testing Market CAGR (growth rate) is expected to be around 7.76% during the forecast period (2025 - 2035). **Key Italy Host Cell Protein Testing Market Trends Highlighted** The Italy Host Cell Protein Testing Market is experiencing some notable developments due to the expansion of the biopharmaceutical industry in the country. The continually increasing number of biotechnology firms situated in Italy equally magnifies the demand for accurate host cell protein testing for compliance with rigid regulatory frameworks. These firms work towards product safety and efficacy, thus resulting in increased demand for testing services. In addition, the Italian authorities are insisting on the use of comprehensive testing methods which in turn increases the development and usage of new testing methods and equipment. This market can be addressed by forming testing partnerships with local biotech companies and laboratories. These partnerships would not only diversify service offerings but also enable the adoption of new testing techniques. Moreover, there is also a strong demand for Italy-based companies that design and manufacture rapid test kits to meet the demand of Italian fabricators, especially with the country’s strong focus on industrial healthcare products. There has been an observable increase in investment in research and development activities within the Italian pharmaceutical industry. The funds are helping to improve the test procedures and also grant access to a variety of collaborations with academic, governmental, and private entities. Additionally, Italy's positioning as a hub for pharmaceutical conferences and workshops is facilitating knowledge sharing about host cell protein testing practices and requirements. All these developments contribute to shaping an increasingly competitive and advanced landscape for host cell protein testing in Italy, aligning closely with global trends while catering to local market needs. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Italy Host Cell Protein Testing Market Drivers** Rising Biopharmaceutical Development in Italy The growth of the biopharmaceutical industry in Italy is a significant driver for the Italy Host Cell Protein Testing Market Industry. Italy is home to numerous biopharmaceutical companies, with over 200 manufacturers actively engaged in the production of biologics and biosimilars. The Italian Ministry of Health has increasingly emphasized the importance of biotechnology in healthcare, earmarking substantial funds for research and development in this area. This investment has resulted in a 25% increase in the number of clinical trials conducted in Italy over the last five years, according to the Italian Medicines Agency (AIFA). Consequently, the escalating demand for host cell protein testing services among these companies is pivotal for ensuring the safety, efficacy, and compliance of their products. With a projected annual increase in biopharmaceutical R investments, the need for reliable testing solutions will continue to fuel growth in the market. Increasing Stringency of Regulatory Guidelines The stringent regulatory landscape in Italy is another key driver contributing to the Italy Host Cell Protein Testing Market Industry. The European Medicines Agency (EMA) has set forth rigorous guidelines pertaining to the safety and efficacy of biological products, with specific mandates regarding host cell protein testing. As a result, pharmaceutical and biotechnology companies are under pressure to comply with these regulations to avoid penalties and ensure product approval. Data from the EMA indicates a 15% rise in the number of submissions rejected due to non-compliance with testing protocols over the past three years. Consequently, this trend compels companies to invest more in advanced testing solutions, which in turn drives market growth. Growing Awareness of Immunotherapy and Personalized Medicine The increased focus on immunotherapy and personalized medicine in Italy significantly boosts the Italy Host Cell Protein Testing Market Industry. Recent industry reports highlight that at least 30 new immunotherapy products are under development in Italian clinical settings, driven by the success of CAR-T cell therapies and immune checkpoint inhibitors. The Italian Society of Hematology has been actively promoting awareness and training regarding these innovative therapeutic approaches. This has led to heightened demand for thorough host cell protein testing to ensure that these therapies meet the highest standards of safety and efficacy, increasing the need for specialized testing services in the region. **Italy Host Cell Protein Testing Market Segment Insights:** **Italy Host Cell Protein Testing Market Type Insights  ** ** ** The Italy Host Cell Protein Testing Market has seen a notable rise, particularly within the Type segment, which is crucial for ensuring the safety and efficacy of biopharmaceutical products. This segment encompasses various methodologies, such as PCR-Based Assays, ELISA-based Assays, Mass Spectrometry-Based Assays, and others, each playing a significant role in the testing landscape. PCR-Based Assays are particularly valued for their specificity and sensitivity in detecting host cell proteins, which is essential for complying with stringent regulatory standards in Italy's biopharmaceutical industry. ELISA-based Assays, on the other hand, offer robustness and reproducibility, making them a preferred choice among laboratories for quantifying host cell proteins in complex samples, thus aiding in process improvements and product safety. Mass Spectrometry-Based Assays have gained favor due to their high-resolution capabilities which allow for detailed analysis of protein structures, making them indispensable in the characterization phase of drug development. Additionally, the landscape includes other testing methodologies that provide versatile options tailored to specific needs, ensuring comprehensive coverage of potential host cell contaminants. The broader market dynamics in Italy, influenced by a growing emphasis on biosimilars and monoclonal antibodies, drive the need for rigorous host cell protein testing methodologies, which, in turn, supports the ongoing advancements in biotechnology and pharmaceutical manufacturing. Moreover, the regulatory landscape in Europe mandates stringent bioanalytical methods, enhancing the significance of these testing types within the Italy Host Cell Protein Testing Market. The consistent evolution in technology, along with expanding applications of biopharmaceuticals, will contribute to an increasing focus on validating and standardizing these assay types, ultimately ensuring the integrity and safety of therapeutic candidates entering clinical trials and commercial markets in Italy. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Host Cell Protein Testing Market End User Insights  ** ** ** The Italy Host Cell Protein Testing Market predominantly serves various end-user sectors, which play a crucial role in the development and commercialization of biopharmaceutical products. Contract Research Organizations (CROs) form a vital part of this landscape, utilizing advanced testing methodologies to assist companies in ensuring the safety and efficacy of biologics. Their agile nature, combined with specialized expertise, allows them to cater to the unique demands of the biopharmaceutical industry. Biopharmaceutical Companies are significant players as well, conducting extensive research to guarantee that their products are free from contaminants, a task critical to patient safety. Their investment in host cell protein testing ensures compliance with stringent regulatory demands, thus upholding the integrity of the Italian biopharmaceutical market. Meanwhile, the Others segment encompasses a variety of stakeholders that contribute to the ecosystem, including academic institutions and government research facilities, which also leverage testing services for innovative biopharmaceutical advancements. As the industry progresses, the emphasis on precise testing and quality assurance in these segments will continue to drive the Italy Host Cell Protein Testing Market forward, supporting market growth and advancements in therapeutic solutions. $IMAGE3_HERE$ Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Italy Host Cell Protein Testing Market Key Players and Competitive Insights:** The competitive landscape of the Italy Host Cell Protein Testing Market is intricately shaped by a variety of factors, including the growing demand for biopharmaceutical products, the increasing focus on quality assurance in biologics, and the rising necessity for regulatory compliance. Companies within this sector are constantly innovating to develop cutting-edge technologies and methodologies for the accurate detection and quantification of host cell proteins. The market is characterized by a mix of established players and emerging participants, all vying for a share of the growing demand driven by advancements in drug development and the need for robust testing methodologies. Key competitors are leveraging partnerships, collaborations, and acquisitions to enhance their market presence and develop comprehensive solutions that cater to the unique needs of biopharmaceutical manufacturers in Italy. Agilent Technologies has a commendable presence in the Italy Host Cell Protein Testing Market, known for its advanced analytical technologies that cater specifically to the rigorous requirements of protein analysis. The company's strengths lie in its cutting-edge solutions, including high-performance liquid chromatography and mass spectrometry, which facilitate accurate detection, quantification, and characterization of host cell proteins. Agilent Technologies is well-regarded for its strong product portfolio and technical expertise, allowing it to provide comprehensive support to biopharmaceutical companies in Italy, ensuring they meet stringent regulatory standards. The commitment of Agilent Technologies to innovation is evident in its continuous investment in research and development, making it a preferred choice for pharmaceutical companies seeking reliable and efficient testing solutions. Merck KGaA operates significantly within the Italy Host Cell Protein Testing Market, offering a diverse range of products and solutions tailored to the biopharmaceutical industry. The company provides critical services related to proteomics, including its specialized kits and assays designed to identify and quantify host cell proteins with precision. Merck KGaA's strengths include a well-established market presence and a reputation for high-quality products that facilitate compliance with rising regulatory requirements. The company is deeply engaged in expanding its reach through strategic mergers and acquisitions, which enhance its portfolio and capabilities in the Italian market. By fostering collaborations with local entities and tapping into the growing demand for biologics, Merck KGaA has positioned itself as a formidable player in host cell protein testing, contributing to the overall growth of biopharmaceutical testing services in Italy. **Key Companies in the Italy Host Cell Protein Testing Market Include:** **Italy Host Cell Protein Testing Market Industry Developments** The Italy Host Cell Protein Testing Market has recently seen significant developments, particularly with major companies like Agilent Technologies, Merck KGaA, and Lonza making strides in advanced testing methodologies. Merck KGaA launched a new range of assays in June 2023 that significantly enhance sensitivity for detecting host cell proteins in biologics, reflecting the growing demand for more accurate testing solutions in Italy's biopharmaceutical sector. Moreover, in October 2023, Thermo Fisher Scientific announced an investment to expand its capabilities in the Italian market, focusing on the development of customized testing solutions for local pharmaceutical companies. The Italian government's commitment to biotechnology innovation, alongside increased funding for research and development, has contributed to a positive market outlook. In terms of mergers and acquisitions, recent months have not reported any significant activity involving the major players in this specific segment. However, companies are continuously looking for partnerships that can enhance their technological capabilities, such as the collaboration between BioRad Laboratories and Eurofins Scientific, announced in March 2023, aiming to streamline host cell protein analysis. The growing emphasis on regulatory compliance and quality assurance in the biopharmaceutical industry continues to drive the demand for advanced host cell protein testing technologies. **Host Cell Protein Testing Market Segmentation Insights** - Host Cell Protein Testing Market Type Outlook - PCR-Based Assays ELISA-based Assays Mass Spectrometry-Based Assays Others - Host Cell Protein Testing Market End User Outlook - Contract Research Organizations Biopharmaceutical Companies Others ## Market Drivers ### Growing Demand for Biosimilars The growing demand for biosimilars in Italy is a significant driver for the host cell-protein-testing market. As healthcare costs rise, there is an increasing shift towards more affordable biosimilar options, which necessitate rigorous testing to ensure their safety and efficacy. The Italian biosimilars market is projected to grow at a CAGR of 15% over the next five years, prompting manufacturers to invest in comprehensive testing protocols. This trend underscores the importance of host cell-protein testing in the development of biosimilars, as it helps to mitigate risks associated with product contamination. Consequently, the host cell-protein-testing market is likely to benefit from this surge in biosimilar production, as companies seek to validate their products through stringent testing. ### Increased Focus on Drug Safety The heightened focus on drug safety in Italy significantly influences the host cell-protein-testing market. Regulatory bodies are enforcing stringent guidelines to ensure that biopharmaceutical products are free from contaminants, including host cell proteins. This regulatory environment compels manufacturers to adopt robust testing practices, thereby driving demand for host cell-protein testing services. In recent years, the Italian Medicines Agency (AIFA) has implemented more rigorous testing requirements, which has resulted in a 20% increase in testing service utilization among biopharmaceutical companies. As the industry continues to prioritize patient safety, the host cell-protein-testing market is expected to experience sustained growth, with companies investing in advanced testing technologies to comply with these regulations. ### Rising Biopharmaceutical Production The increasing production of biopharmaceuticals in Italy is a key driver for the host cell-protein-testing market. As biopharmaceutical companies expand their operations, the demand for rigorous testing of host cell proteins becomes paramount to ensure product safety and efficacy. In 2025, the biopharmaceutical sector in Italy is projected to reach a market value of approximately €5 billion, highlighting the need for advanced testing solutions. This growth is likely to stimulate investments in testing technologies and services, thereby enhancing the overall landscape of the host cell-protein-testing market. Furthermore, the emphasis on quality control in biopharmaceutical manufacturing necessitates comprehensive testing protocols, which could lead to increased adoption of host cell-protein testing methodologies. ### Investment in Research and Development Investment in research and development (R&D) within the biopharmaceutical sector is a crucial driver for the host cell-protein-testing market. Italian companies are increasingly allocating resources towards R&D to innovate and improve their product offerings. This focus on R&D is expected to lead to the development of novel therapeutics, which will require extensive testing for host cell proteins to ensure compliance with regulatory standards. In 2025, R&D spending in the biopharmaceutical industry in Italy is projected to exceed €1 billion, indicating a robust commitment to advancing testing methodologies. As companies strive to enhance their competitive edge, the demand for host cell-protein testing services is likely to rise, further propelling market growth. ### Emergence of Advanced Analytical Techniques The emergence of advanced analytical techniques is reshaping the host cell-protein-testing market in Italy. Innovations such as mass spectrometry and high-performance liquid chromatography (HPLC) are enhancing the sensitivity and specificity of host cell-protein detection. These technologies enable more accurate quantification of host cell proteins, which is crucial for biopharmaceutical quality assurance. As of 2025, the adoption of these advanced techniques is anticipated to increase by 30%, driven by the need for precise testing in the biopharmaceutical sector. This trend not only improves testing outcomes but also encourages the development of new testing methodologies, thereby expanding the capabilities of the host cell-protein-testing market. ## Future Outlook The [Host Cell Protein Testing Market](https://www.marketresearchfuture.com/reports/host-cell-protein-testing-market-10651) in Italy is projected to grow at a 5.82% CAGR from 2025 to 2035, driven by increasing biopharmaceutical production and regulatory demands. **New opportunities:** - Development of automated testing platforms for enhanced efficiency. - Expansion of service offerings to include comprehensive data analytics. - Partnerships with biotech firms for tailored testing solutions. By 2035, the market is expected to achieve robust growth, positioning itself as a leader in biopharmaceutical quality assurance. ## Segment Insights ### By Type: ELISA-based Assays (Largest) vs. PCR-Based Assays (Fastest-Growing) In the Italy host cell-protein-testing market, ELISA-based assays lead the segment, showcasing a robust presence due to their reliability and widespread acceptance in diagnostics. These assays account for a significant market share, driven by their ability to effectively detect and quantify proteins in various biological samples. Conversely, PCR-based assays are emerging rapidly, reflecting a growing preference among researchers for their high sensitivity and specificity, particularly in genetic and infectious disease testing. Current trends indicate a dynamic shift towards PCR-based assays, which have become the fastest-growing segment within the market. The increasing demand for rapid and accurate testing solutions, especially in the context of infectious diseases and biotechnology applications, is propelling this growth. As technology advances, the integration of automation and improved analytics in PCR methods is likely to enhance their adoption, further pushing their market position. Assays: ELISA-based (Dominant) vs. PCR-based (Emerging) ELISA-based assays dominate the Italy host cell-protein-testing market due to their established reliability, ease of use, and ability to handle a variety of sample types. This established method is widely utilized for protein quantification, making it a preferred choice in clinical laboratories. In contrast, PCR-based assays represent an emerging trend, characterized by their exceptional sensitivity and speed in detecting nucleic acids. Their growing popularity is fueled by advancements in technology, allowing for quicker results and higher throughput. This emerging segment is particularly favored in research and clinical settings focused on infectious diseases, thereby positioning PCR-based assays as a crucial player in the evolving landscape of protein testing. ### By End User: Biopharmaceutical Companies (Largest) vs. Contract Research Organizations (Fastest-Growing) In the Italy host cell-protein-testing market, the distribution among end users is primarily dominated by biopharmaceutical companies, which hold a substantial market share due to their extensive involvement in drug development and a growing focus on biologics. Contract research organizations (CROs) follow, leveraging their expertise and resources to support biopharmaceutical companies in testing and development processes. Others, which include academic and research institutions, play a smaller yet significant role in advancing exploratory research and innovation. The growth trends within the end user segment indicate that biopharmaceutical companies will continue to be the driving force, supported by increasing investments in R&D. Meanwhile, CROs are rapidly emerging as the fastest-growing segment due to the rising demand for outsourcing testing services and enhanced focus on cost-effective solutions among biopharmaceutical firms. As the industry evolves, collaborations between these entities are likely to further stimulate growth and innovation in the market. Biopharmaceutical Companies (Dominant) vs. Contract Research Organizations (Emerging) Biopharmaceutical companies represent the dominant force in the Italy host cell-protein-testing market, characterized by their investment capacity, advanced technological infrastructure, and regulatory knowledge. Their focus on biologics and personalized medicine drives the demand for accurate protein testing solutions. On the other hand, contract research organizations are considered an emerging segment, catering to the evolving needs of biopharmaceutical companies by providing specialized services. These organizations offer flexibility, scalability, and cost-effectiveness, making them an attractive option for smaller biotech firms and startups. The collaboration between these two segments is pivotal, as it leads to increased efficiencies and innovative approaches in drug development and testing protocols. ## Competitive Benchmarking The host cell-protein-testing market in Italy is characterized by a dynamic competitive landscape, driven by increasing demand for biopharmaceuticals and stringent regulatory requirements. Key players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and Sartorius AG (DE) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. These companies focus on developing advanced testing solutions that ensure the safety and efficacy of biologics, thereby shaping a competitive environment that emphasizes quality and compliance.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with a mix of established players and emerging firms. The collective influence of these key players fosters a competitive structure that encourages innovation while also addressing the complexities of regulatory compliance and customer demands. In October Thermo Fisher Scientific (US) announced the launch of a new suite of host cell protein testing kits designed to streamline the testing process for biopharmaceutical manufacturers. This strategic move is likely to enhance their product portfolio and strengthen their position in the market by providing customers with more efficient and reliable testing solutions. The introduction of these kits reflects a broader trend towards automation and efficiency in laboratory processes. In September Merck KGaA (DE) expanded its collaboration with a leading Italian biopharmaceutical company to develop customized testing solutions for host cell proteins. This partnership not only underscores Merck's commitment to innovation but also highlights the importance of localized collaborations in addressing specific market needs. Such strategic alliances may enhance their competitive edge by allowing for tailored solutions that meet the unique requirements of regional clients. In August Sartorius AG (DE) acquired a small biotech firm specializing in advanced analytics for host cell protein testing. This acquisition is indicative of Sartorius's strategy to bolster its capabilities in analytical testing, which is increasingly critical in the biopharmaceutical sector. By integrating these advanced technologies, Sartorius is likely to enhance its service offerings and improve its competitive positioning in the market. As of November current trends in the host cell-protein-testing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in testing processes. Strategic alliances are becoming increasingly vital, as companies seek to combine resources and expertise to drive innovation. The competitive differentiation is expected to evolve, shifting from price-based competition to a focus on technological advancements, reliability in supply chains, and the ability to meet stringent regulatory standards. This transition suggests that companies prioritizing innovation and quality will likely emerge as leaders in the market. ## Recent News & Developments The Italy Host Cell Protein Testing Market has recently seen significant developments, particularly with major companies like Agilent Technologies, Merck KGaA, and Lonza making strides in advanced testing methodologies. Merck KGaA launched a new range of assays in June 2023 that significantly enhance sensitivity for detecting host cell proteins in biologics, reflecting the growing demand for more accurate testing solutions in Italy's biopharmaceutical sector. Moreover, in October 2023, Thermo Fisher Scientific announced an investment to expand its capabilities in the Italian market, focusing on the development of customized testing solutions for local pharmaceutical companies. The Italian government's commitment to biotechnology innovation, alongside increased funding for research and development, has contributed to a positive market outlook. In terms of mergers and acquisitions, recent months have not reported any significant activity involving the major players in this specific segment. However, companies are continuously looking for partnerships that can enhance their technological capabilities, such as the collaboration between BioRad Laboratories and Eurofins Scientific, announced in March 2023, aiming to streamline host cell protein analysis. The growing emphasis on regulatory compliance and quality assurance in the biopharmaceutical industry continues to drive the demand for advanced host cell protein testing technologies. ## Report Scope | MARKET SIZE 2024 | 24.15(USD Million) | | --- | --- | | MARKET SIZE 2025 | 25.56(USD Million) | | MARKET SIZE 2035 | 45.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.82% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Sartorius AG (DE), Lonza Group (CH), GenScript Biotech Corporation (CN), Charles River Laboratories (US), WuXi AppTec (CN), Bio-Rad Laboratories (US) | | Segments Covered | Type, End User | | Key Market Opportunities | Growing demand for advanced host cell-protein-testing technologies driven by regulatory compliance and biopharmaceutical innovation. | | Key Market Dynamics | Rising regulatory scrutiny drives demand for advanced host cell-protein-testing solutions in Italy's biopharmaceutical sector. | | Countries Covered | Italy | ## Frequently Asked Questions **Q: What is the current market valuation of the host cell-protein-testing market in Italy?** A: The market valuation was $24.15 Million in 2024. **Q: What is the projected market size for the host cell-protein-testing market in Italy by 2035?** A: The projected market size is expected to reach $45.0 Million by 2035. **Q: What is the expected CAGR for the host cell-protein-testing market in Italy during the forecast period 2025 - 2035?** A: The expected CAGR is 5.82% during the forecast period 2025 - 2035. **Q: Which companies are the key players in the host cell-protein-testing market in Italy?** A: Key players include Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Lonza Group, GenScript Biotech Corporation, Charles River Laboratories, WuXi AppTec, and Bio-Rad Laboratories. **Q: What are the main types of assays used in the host cell-protein-testing market in Italy?** A: Main types of assays include PCR-Based Assays, ELISA-based Assays, Mass Spectrometry-Based Assays, Liquid Chromatography–Mass Spectrometry (LC–MS), and Tandem Mass Spectrometry (MS/MS). **Q: How did the PCR-Based Assays segment perform in 2024?** A: The PCR-Based Assays segment was valued at $5.0 Million in 2024 and is projected to grow. **Q: What is the valuation of the ELISA-based Assays segment in 2024?** A: The ELISA-based Assays segment was valued at $6.0 Million in 2024. **Q: What is the expected growth for the Biopharmaceutical Companies segment in the host cell-protein-testing market?** A: The Biopharmaceutical Companies segment is projected to grow from $12.0 Million in 2024 to $24.0 Million by 2035. **Q: What is the valuation of the Contract Research Organizations segment in 2024?** A: The Contract Research Organizations segment was valued at $8.0 Million in 2024. **Q: What trends are anticipated for the host cell-protein-testing market in Italy by 2035?** A: Trends suggest a steady growth trajectory, with the market expected to reach $45.0 Million by 2035, driven by advancements in assay technologies. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/italy-host-cell-protein-testing-market-44889*